Isomorphic Labs Raises $5B to Push AI Drugs to Trials
Isomorphic Labs, the Alphabet drug-discovery company led by Demis Hassabis, has raised a $5 billion Series C co-led by Greenoaks and Sequoia, six months after its $2.1 billion Series B. It says its AI-designed candidates in oncology and immunology are showing positive preclinical results, and the money will carry its first programs toward clinical trials.
Isomorphic Labs, the London drug-discovery company spun out of Google DeepMind in 2021, announced a $5 billion Series C on November 17. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and several other new investors and what the company calls continued significant investment from Alphabet. Every existing investor came back: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose a valuation; TechCrunch notes that Bloomberg reported earlier in November that it was seeking money at $50 billion.
The size of the jump is the story. Isomorphic closed a $2.1 billion Series B led by Thrive in May, after a $600 million first round in March 2025. Six months later it has raised more than twice as much again, in a round its press release describes as oversubscribed.
From an engine to a pipeline
The money goes to IsoDDE, the company’s drug design engine, which it describes as a suite of foundational simulation models that work across therapeutic areas and drug modalities, paired with “proprietary agents” that reason over complex biological systems. The release says this work is producing positive preclinical results, in its internal oncology and immunology programs and with partners, and is “setting the stage for clinical entry.” Isomorphic gives no date for a first trial. It says the proceeds will also pay for AI-first translational and clinical development infrastructure, a partner ecosystem for studying disease biology, and what it calls global infrastructure for AI-led bioengineering. According to TechCrunch, its partners include Eli Lilly, Novartis and Johnson & Johnson.
“Our drug design engine is generating molecules with unprecedented precision and speed,” said Sir Demis Hassabis, Isomorphic’s founder and CEO, adding that the round would help drive “our first therapeutic programs towards clinical trials.” President Max Jaderberg said the company was “making repeatable scientific advancements” every week. For Greenoaks, founder Neil Mehta called drug development “an optimization challenge of almost infinite scale,” and Sequoia partner Konstantine Buhler said the team was turning advanced AI into “a growing portfolio of drug candidates.”
Isomorphic’s work grows out of DeepMind’s AlphaFold protein-structure research, and it has offices in London, Cambridge, Massachusetts and Lausanne. The round makes it one of the best-funded private companies in AI-led drug discovery, at a moment when frontier labs are moving into the same field: Anthropic started its own drug-discovery program in July. Isomorphic has now raised more than $7 billion without a single candidate in a clinical trial, so the first one to reach patients is the milestone its next round will be priced on.
Want AI news before everyone else?
The morning's most important AI stories, straight to your inbox. No fluff.